Literature DB >> 19749756

Interferon-alfa, interferon-lambda and hepatitis C.

Thomas R O'Brien.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19749756     DOI： 10.1038/ng.453

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


× No keyword cloud information.
  12 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29.

Authors:  Jukka Sirén; Jaana Pirhonen; Ilkka Julkunen; Sampsa Matikainen
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

Review 3.  Beyond odds ratios--communicating disease risk based on genetic profiles.

Authors:  Peter Kraft; Sholom Wacholder; Marilyn C Cornelis; Frank B Hu; Richard B Hayes; Gilles Thomas; Robert Hoover; David J Hunter; Stephen Chanock
Journal:  Nat Rev Genet       Date:  2009-04       Impact factor: 53.242

4.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

5.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Authors:  Sergei V Kotenko; Grant Gallagher; Vitaliy V Baurin; Anita Lewis-Antes; Meiling Shen; Nital K Shah; Jerome A Langer; Faruk Sheikh; Harold Dickensheets; Raymond P Donnelly
Journal:  Nat Immunol       Date:  2002-12-16       Impact factor: 25.606

6.  Lambda interferon inhibits hepatitis B and C virus replication.

Authors:  Michael D Robek; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 7.  Global epidemiology of hepatitis C virus infection.

Authors:  Colin W Shepard; Lyn Finelli; Miriam J Alter
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

Review 8.  NIH Consensus Statement on Management of Hepatitis C: 2002.

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Jun 10-12

Review 9.  Chronic hepatitis C virus infection: genotyping and its clinical role.

Authors:  D Scott Bowden; Mark D Berzsenyi
Journal:  Future Microbiol       Date:  2006-06       Impact factor: 3.165

10.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330
View more
  28 in total

Review 1.  Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factors.

Authors:  Allan Hildesheim; Cheng-Ping Wang
Journal:  Semin Cancer Biol       Date:  2012-01-25       Impact factor: 15.707

2.  An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.

Authors:  Robert P Myers; Alnoor Ramji; Marc Bilodeau; Stephen Wong; Jordan J Feld
Journal:  Can J Gastroenterol       Date:  2012-06       Impact factor: 3.522

3.  IL28B-genotype testing now and in the era of direct-acting antiviral agents.

Authors:  Timothy R Morgan; Thomas R O'Brien
Journal:  Clin Gastroenterol Hepatol       Date:  2010-12-23       Impact factor: 11.382

4.  Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential.

Authors:  Thomas R O'Brien; Howard A Young; Raymond P Donnelly; Ludmila Prokunina-Olsson
Journal:  J Interferon Cytokine Res       Date:  2019-04-17       Impact factor: 2.607

Review 5.  Novel therapies for hepatitis C - one pill fits all?

Authors:  Michael P Manns; Thomas von Hahn
Journal:  Nat Rev Drug Discov       Date:  2013-06-28       Impact factor: 84.694

6.  HBV life cycle and novel drug targets.

Authors:  Daniel Grimm; Robert Thimme; Hubert E Blum
Journal:  Hepatol Int       Date:  2011-03-08       Impact factor: 6.047

7.  Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.

Authors:  Neal D Freedman; Teresa M Curto; Karen L Lindsay; Elizabeth C Wright; Rashmi Sinha; James E Everhart
Journal:  Gastroenterology       Date:  2011-03-02       Impact factor: 22.682

Review 8.  Immune checkpoint blockade and interferon-α in melanoma.

Authors:  Imran Rafique; John M Kirkwood; Ahmad A Tarhini
Journal:  Semin Oncol       Date:  2015-02-14       Impact factor: 4.929

Review 9.  Genomics and drug response.

Authors:  Liewei Wang; Howard L McLeod; Richard M Weinshilboum
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

10.  MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.

Authors:  Takayoshi Shirasaki; Masao Honda; Tetsuro Shimakami; Rika Horii; Taro Yamashita; Yoshio Sakai; Akito Sakai; Hikari Okada; Risa Watanabe; Seishi Murakami; MinKyung Yi; Stanley M Lemon; Shuichi Kaneko
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.